ClinVar Miner

Submissions for variant NM_001167.4(XIAP):c.1099+2T>C

dbSNP: rs2148097889
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001377125 SCV001574365 likely pathogenic X-linked lymphoproliferative disease due to XIAP deficiency 2021-05-18 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 5 of the XIAP gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in XIAP are known to be pathogenic (PMID: 17080092, 21119115, 25666262). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis (PMID: 21674762). This variant is not present in population databases (ExAC no frequency).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.